Nurix Therapeutics (NRIX) Competitor Comparison
We are evaluating the key criteria listed to compare Nurix Therapeutics (NRIX) against its competitors in the Biotechnology industry.
Market Capitalization
162 / 368Gross Profits
252 / 278Total Revenue
107 / 300EBITDA
249 / 337Free Cashflow
244 / 352Quick Ratio
205 / 357Earnings per Share
254 / 359Dividend yield
0 / 6Total Cash
125 / 358Performance 3 years
116 / 368Performance 5 years
100 / 368Performance 10 years
81 / 368Linearity 3 years
55 / 368Linearity 5 years
108 / 368Linearity 10 years
92 / 368Total Rank
210 / 368Dividend Rank
220 / 368Valuation Rank
282 / 368Piotroski Rank
226 / 368Muliplier Rank
165 / 368Earnings per Share - NRIX ranking 254 / 359
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.